Article
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
Journal of the National Cancer Institute - 3 Jul 2013
Loi Sherene, Michiels Stefan, Lambrechts Diether, Fumagalli Debora, Claes Bart, Kellokumpu-Lehtinen Pirkko-Liisa, Bono Petri, Kataja Vesa, Piccart Martine J, Joensuu Heikki, Sotiriou Christos
Abstract excerpt
BACKGROUND: Certain somatic alterations in breast cancer can define prognosis and response to therapy. This study investigated the frequencies, prognostic effects, and predictive effects of known cancer somatic mutations using a randomized, adjuvant, phase III clinical trial dataset. METHODS: The FinHER trial was a phase III, randomized adjuvant breast cancer trial involving 1010 women. Patients with human...
Topics
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Base Sequence
- Biomarkers, Tumor
- Breast Neoplasms
- Class I Phosphatidylinositol 3-Kinases
- Cyclophosphamide